[KRX KOSDAQ Trading Value 2600 Trillion] 'Pharmaceuticals & Bio' Leading the Rise in KOSDAQ

The Chairman Utilizes the Opportunity to Accumulate Pharmaceutical and Bio Stocks

On the afternoon of the 21st, an employee is working in the dealing room at the Hana Bank headquarters in Jung-gu, Seoul. On this day, the KOSDAQ closed at 953.58, up 6.34 points (0.67%) from the previous day. (Photo by Yonhap News)

[Asia Economy Reporter Kum Boryeong] As the KOSDAQ recently surpassed the 950-point mark and continued its upward rally, 'pharmaceutical and bio' stocks led the KOSDAQ's rising trend. This was because buying interest from individuals and foreigners concentrated on pharmaceutical and bio stocks.

According to the Korea Exchange on the 23rd, during the 9 trading days from the 9th to the 21st when the KOSDAQ's upward trend continued, foreigners purchased 109.2 billion KRW worth of Celltrion Healthcare shares. The KOSDAQ index rose from 906.84 on the 8th to 953.58 on the 21st.

In particular, during this period, the top net purchase stocks by foreigners in the KOSDAQ market were pharmaceutical and bio stocks, ranking from first place Celltrion Healthcare, followed by Seegene, Alteogen, Samchundang Pharm, Helixmith, and Cellivery up to sixth place. Individuals also showed interest in pharmaceutical and bio stocks by placing Enzen Bio, Quantamatrix, and SCM Lifescience among the top 10 net purchases during the same period.

The correction phase was used as an opportunity to accumulate pharmaceutical and bio stocks. On the previous day, while the KOSDAQ index fell 2.61% (24.85 points) compared to the previous trading day, individual investors bought the most of Precision Bio (77.6 billion KRW), Celltrion Healthcare (67.3 billion KRW), GoBioLab (30 billion KRW), Celltrion Pharm (20.1 billion KRW), and Samchundang Pharm (15.5 billion KRW) in that order. Although foreign investors net sold 175.7 billion KRW in the KOSDAQ market, they included Seegene (6.6 billion KRW), Helixmith (6.6 billion KRW), Alteogen (3.7 billion KRW), and ST Pharm (3.6 billion KRW) in their portfolios.

The level of interest in pharmaceutical and bio sectors this year can be gauged simply by looking at the KOSDAQ market capitalization rankings. As of the previous day, the top market cap in the KOSDAQ market was Celltrion Healthcare. Following were Celltrion Pharm, Seegene, HL Biopharma, and Alteogen, with all top five spots occupied by pharmaceutical and bio stocks. At the beginning of the year, the order was Celltrion Healthcare, HL Biopharma, CJ ENM, Pearl Abyss, and KMW.

Seegene and Alteogen have grown significantly through the COVID-19 pandemic phase. At the beginning of the year, their market caps were 811.9 billion KRW and 970 billion KRW respectively, which increased to 5.1051 trillion KRW and 4.4708 trillion KRW as of the previous day.